AstraZeneca is making a $2 billion equity investment in Summit Therapeutics, the company that holds Western rights to ivonescimab, one of the most closely watched cancer drugs in development. Alongside the investment, announced on September 29, 2026, the two companies will collaborate on trials combining ivonescimab with AstraZeneca’s antibody-drug conjugates (ADCs), starting in gastrointestinal cancers.

The deal

AstraZeneca is buying Summit shares at $18.36 each, an 18.6% premium to the prior closing price. Unusually for a big-pharma deal of this size, it is not a licensing or acquisition: each company keeps the rights to its own drugs. Summit retains ivonescimab rights across the Americas, Europe, the Middle East, Africa and Japan. AstraZeneca is expected to sponsor the combination trials, with costs shared. A non-binding memorandum of understanding leaves room to test ivonescimab with other AstraZeneca cancer drugs later.

What ivonescimab is

Ivonescimab, discovered by China’s Akeso, is a bispecific antibody — a single molecule that binds two targets. One arm blocks PD-1, the “brake” on immune T cells that drugs like Merck’s Keytruda release so the immune system can attack tumors. The other blocks VEGF, a signal tumors use to grow new blood vessels. Combining the two in one molecule is designed to concentrate activity in the tumor, where both targets are abundant. In a Phase 3 trial in China, ivonescimab beat Keytruda head to head in a type of lung cancer, a result that made it one of the most talked-about drugs in oncology. It is approved in China for lung cancers but not yet in the US or Europe.

What ADCs add

ADCs are antibodies that carry a potent chemotherapy payload directly to cancer cells bearing a particular marker, sparing more healthy tissue than conventional chemotherapy. AstraZeneca has built one of the industry’s largest ADC portfolios and has said it wants ADCs to become the “backbone” of treatment across tumor types, combined with next-generation immunotherapies. As executive vice president Susan Galbraith put it, broadening the reach of the ADC portfolio in combination with such immunotherapies is a core pillar of the company’s oncology strategy.

The first targets: gastric and biliary cancers

The first trials will pair ivonescimab with AstraZeneca’s ADC sonesitatug vedotin (sone-ve), which targets claudin 18.2, a protein found on many stomach cancers. Sone-ve recently met its primary endpoint of improved overall survival in a Phase 3 gastric cancer trial. The collaboration will study the combination in CLDN18.2-positive gastric cancer and in biliary tract cancer, cancers of the bile ducts and gallbladder, where ivonescimab has shown statistically significant improvement in preliminary Phase 3 results. Both are cancers with poor outlooks and limited options, so effective combinations could matter a great deal. Stomach cancer is especially common in East Asia, and biliary tract cancers are often diagnosed late, when surgery is no longer possible and survival is typically measured in months.

A crowded race for PD-1/VEGF drugs

Ivonescimab’s win over Keytruda set off a wave of dealmaking for similar two-target antibodies, most of them discovered in China. In 2025, Pfizer licensed a PD-1/VEGF bispecific from 3SBio, and Bristol Myers Squibb partnered with BioNTech on another, each paying well over $1 billion upfront; Merck itself had earlier licensed a candidate from LaNova. The stakes are high because PD-1 drugs are the largest class in oncology — Keytruda alone is the world’s best-selling medicine — and a successor that works better in common cancers such as lung cancer could reshape the market as Keytruda’s key patents expire later this decade. AstraZeneca, which sells its own PD-L1 drug, Imfinzi, gains access to a leading bispecific without buying it outright.

Why a stake rather than a license?

A minority equity investment lets AstraZeneca align closely with Summit, and gain a seat in ivonescimab’s development, without paying the much larger sum a full licensing deal or acquisition would demand. For Summit, it brings substantial cash to fund expensive global Phase 3 trials without giving up its commercial rights. It also signals industry confidence in the PD-1/VEGF bispecific class, which several other large drugmakers have entered through deals with Chinese biotechs.

The caveats

Ivonescimab’s strongest data so far come from trials run in China; regulators and doctors will want to see results in more diverse, global populations. Summit’s own Western trials have produced mixed signals in some settings, and the FDA has yet to approve the drug. Combining two active drugs can also raise side effects. The collaboration’s success will depend on combination trials that have not yet read out.

What it means

For patients, the deal is a long-term bet rather than an immediate change: the combination trials will take years. For the industry, it underlines two trends — the rise of bispecific immunotherapies challenging Keytruda’s dominance, and ADC-plus-immunotherapy combinations as the next frontier in cancer treatment. This is business news, not investment or medical advice.